FDA Rx-To-OTC Switch Division Director Leonard-Segal Resigns
This article was originally published in The Tan Sheet
Andrea Leonard-Segal’s leadership in FDA’s OTC program helped shift the agency toward considering an expanded switch paradigm, and her successor will enter a challenging regulatory environment, stakeholders say.
You may also be interested in...
Commissioner Hamburg says FDA asked for input on a “new paradigm” for nonprescription drug approvals in part because pharmaceutical firms have concerns about whether potential access restrictions imposed on an innovating switch would also apply to generic versions that eventually reach the market.
Dietary ingredients identified in recent FDA warning letters as linked to disease claims by marketers directing customers to scientific literature include omega-3 fatty acid, ginkgo biloba, glucosamine curcumin and vitamin D.
Approvals by FDA also include revised container and consumer information labeling for J&J's Men’s Rogaine to align with labeling for Women’s Rogaine; bonus-pack labeling for Bayer AG’s Aleve; and